Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma

Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improveme...

Full description

Bibliographic Details

Published in:	Cancer research communications Vol. 4; no. 1; pp. 18 - 27
Main Authors:	Badhai, Jitendra, Landman, Nick, Pandey, Gaurav Kumar, Song, Ji-Ying, Hulsman, Danielle, Krijgsman, Oscar, Chandrasekaran, Gayathri, Berns, Anton, van Lohuizen, Maarten
Format:	Journal Article
Language:	English
Published:	United States American Association for Cancer Research 03.01.2024
Subjects:	Animals Biomarkers Enhancer of Zeste Homolog 2 Protein - genetics Humans Lung Cancer Lung Neoplasms - drug therapy Melanoma - drug therapy Mesothelioma - drug therapy Mesothelioma, Malignant Mice Preclinical Models Small Molecule Agents Translational Research Tumor Suppressor Proteins - genetics Ubiquitin Thiolesterase - genetics
ISSN:	2767-9764, 2767-9764
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!